Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22262985 | 0.89 | GPR84 (0.38) | CYP1A2CYP2D6HIF1AMEN1KMT2A | |
| SCHEMBL22275736 | 0.88 | CYP1A2 (0.50) | CYP1A2CYP2D6HIF1ASIGMAR1MEN1 | |
| SCHEMBL20917799 | 0.87 | CYP1A2 (0.44) | CYP1A2CYP2D6HIF1ASIGMAR1MEN1 | |
| SCHEMBL22263120 | 0.86 | DAO (0.42) | SIGMAR1HTR2A | |
| SCHEMBL20932774 | 0.86 | CYP1A2 (0.48) | CYP1A2CYP2D6HIF1ASIGMAR1MEN1 | |
| SCHEMBL22275641 | 0.85 | KMT2A (0.42) | CYP1A2CYP2D6MEN1KMT2AKCNH2 | |
| SCHEMBL20920181 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP2D6HIF1ASIGMAR1MEN1 | |
| SCHEMBL22275610 | 0.83 | PPARD (0.38) | CYP1A2CYP2D6TSHR | |
| SCHEMBL20917798 | 0.82 | SLC6A4 (0.36) | CYP1A2CYP2D6SLC6A4TSHR | |
| SCHEMBL20932763 | 0.81 | MAPT (0.41) | GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239452-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | CYP1A2 363/4885CYP2D6 575/4885HIF1A 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.